Superworth

Heron Therapeutics price to sales ratio HRTX

Market value divided by revenue over the last twelve months, since 2018.

Today, Nov 2, 2026
0.4×
9-year median
4.3×
Against its 9-year history
0th
percentile: 0 is its lowest day, 100 its highest
9-year range
0.3× to 76.9×
Peer median
1.1×

Heron Therapeutics' price to sales ratio is 0.4× as of Nov 2, 2026.

That is below its 9-year median of 4.3×, lower than on 100% of days in the last 9 years.

Over that time it ranged from 0.3× in Oct 2026 to 76.9× in Jun 2018.

The median for 7 large drugmakers of a similar size is 1.1×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far0.4×0.3×1.8×
20251.5×1.2×2.6×
20241.7×1.2×4.2×
20232.1×0.7×3.8×
20223.0×2.6×10.4×
202110.8×10.3×20.3×
202018.6×7.0×18.6×
201915.5×11.7×36.7×
201831.6×29.5×76.9×

Against its peers

Companies in Drug Manufacturers - General nearest Heron Therapeutics' size, closest first, today.

CompanyPrice to sales ratio
HRTXHeron Therapeutics0.4×
SPROSpero Therapeutics1.3×
ATNMActinium Pharmaceuticalsn/m
LFVNLifevantage0.4×
NATRNatures Sunshine Products0.4×
CRMDCorMedix0.9×
ARVNArvinas1.6×
PBYIPuma Biotechnology2.3×
Peer median1.1×

Where Heron Therapeutics ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Heron Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.